Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
Open Access
- 1 May 2012
- journal article
- review article
- Published by Taylor & Francis in Core Evidence
- Vol. 7, 29-38
Abstract
Peer reviewed article authored by (Parhofer KG). Read article or submit your manuscript for publishing.Keywords
This publication has 36 references indexed in Scilit:
- Familial Hypercholesterolemia: Present and Future ManagementCurrent Cardiology Reports, 2011
- Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial HypercholesterolemiaJournal of Clinical Lipidology, 2011
- Drugs in development for management of lipoprotein disordersJournal of Clinical Lipidology, 2011
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial HypercholesterolemiaThe American Journal of Cardiology, 2010
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemiaJournal of Lipid Research, 2010
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin TherapyJACC, 2010
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 2008
- HDL Metabolism and CETP InhibitionCardiology in Review, 2008
- Independent Mutations at Codon 3500 of the Apolipoprotein B Gene Are Associated With HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995